GPT and anemia: The most common adverse events of all grades in the ALEX trial with a difference in frequency of 5% or more compared to crizotinib were anemia (20%), peripheral edema (17%), myalgia (16%), increased ALT (15%), increased AST (14%), increased blood bilirubin (15%), nausea (14%), and diarrhea (12%).